Home＞REGULATORY
Payer Rep Insists CEA-Based Price Hike “Not an Option,” MHLW Wants “Grounds” for That Argument: Chuikyo(Oct.26.2017)
Medical Economics Division Director Masami Sakoi Preparing for Chuikyo CEA Joint Meeting |
As a vocal payer member of a key reimbursement policy panel continues to stand against a possible price raise under an as-yet-elusive cost-effective assessment scheme in Japan, a health ministry official chafed at his refusal on October 25, asking for “grounds” for his argument ...
(LOG IN FOR FULL STORY)
-
- MHLW Proposes New Approval Framework Incorporating Conditional OK, Sakigake Scheme Oct.19
- Council Approves MHLW’s Plan to Deal with Difficult-to-Develop Drugs and Indications Oct.19
-
PMDA to Focus on Proper Use of Sakigake and Conditional Approval Systems in Its 4th Midterm Plan
Oct.19
- Council OKs Public Knowledge-Based Applications for Add’l Pediatric Indications for Blopress Oct.19
-
Chuikyo Wary on CEA Use for Reimbursement Decisions as MHLW Sorts Out Discussion Points towards Full Rollout
Oct.18
- MHLW Proposes New Approval Framework Incorporating Conditional OK, Sakigake Scheme(Oct.19)
- Prescribers Asked to Stop New Enbrel Biosimilar Use as Maker Can’t Keep Up with Demand(Oct.19)
- Council Approves MHLW’s Plan to Deal with Difficult-to-Develop Drugs and Indications(Oct.19)
- PMDA to Focus on Proper Use of Sakigake and Conditional Approval Systems in Its 4th Midterm Plan(Oct.19)
- Takeda Earns Japan Clearance for Shire Acquisition(Oct.19)
